Royal Bank of Canada
AVTX icon

Royal Bank of Canada’s Avalo Therapeutics AVTX Stock Holding History

Royal Bank of Canada’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Buy
+216
New +$3.38K ﹤0.01% 6666
2025
Q2 		– Sell
-212
Closed -$2K – 7014
2025
Q1 		$2K Sell
212
-117,144
-100% -$888K ﹤0.01% 6548
2024
Q4 		$872K Buy
+117,356
New +$1.25M ﹤0.01% 3667
2024
Q3 		– Sell
-590
Closed -$7K – 6836
2024
Q2 		$7K Buy
590
+268
+83% +$3.48K ﹤0.01% 6436
2024
Q1 		$7K Buy
322
+184
+133% +$991 ﹤0.01% 6313
2023
Q4 		$1K Buy
138
+136
+6,800% +$3.06K ﹤0.01% 6890
2023
Q3 		$0 Sell
2
-4
-67% -$179 ﹤0.01% 7070
2023
Q2 		$1K Buy
6
+1
+20% +$673 ﹤0.01% 6958
2023
Q1 		$2K Buy
5
+3
+150% +$2.36K ﹤0.01% 6749
2022
Q4 		$2K Buy
+2
New +$2.61K ﹤0.01% 6910
2022
Q3 		– Sell
-1
Closed -$2K – 7430
2022
Q2 		$2K Hold
1
– – ﹤0.01% 6915
2022
Q1 		$3K Sell
1
-4
-80% -$10K ﹤0.01% 7374
2021
Q4 		$24K Buy
5
+3
+150% +$18K ﹤0.01% 6714
2021
Q3 		$15K Buy
2
+1
+100% +$8.11K ﹤0.01% 6808
2021
Q2 		$12K Hold
1
– – ﹤0.01% 6795
2021
Q1 		$13K Hold
1
– – ﹤0.01% 6669
2020
Q4 		$7K Buy
+1
New +$6.95K ﹤0.01% 6518
2020
Q3 		– Hold
0
– – – 6605
2020
Q2 		– Hold
0
– – – 6610
2020
Q1 		– Sell
-1
Closed -$10.6K – 6396
2019
Q4 		$9K Buy
+1
New +$10.5K ﹤0.01% 6170
2019
Q3 		– Hold
0
– -$1K – 6686
2019
Q2 		– Hold
0
– – – 6674
2018
Q4 		– Hold
0
– – – 6732
2018
Q3 		– Hold
0
– – – 6706
2018
Q2 		– Hold
0
– – – 6504
2018
Q1 		– Hold
0
– – – 6326
2017
Q4 		– Hold
0
– – – 6529
2017
Q3 		– Hold
0
– – – 6702

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Royal Bank of Canada's AVTX Position: Q1 2026 in Review

Royal Bank of Canada opened a new position in Avalo Therapeutics (AVTX) in Q1 2026: 216 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #6666 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in AVTX as recently as Q1 2025.

Royal Bank of Canada first reported a position in AVTX in Q4 2019 and has held it in 18 quarters since. The position peaked at $872K in Q4 2024. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Royal Bank of Canada held 216 shares of Avalo Therapeutics worth $2K as of Q1 2026.
  • Avalo Therapeutics was a new Royal Bank of Canada position in Q1 2026.
  • Avalo Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6666 holding.
  • Royal Bank of Canada first reported a position in Avalo Therapeutics in Q4 2019 and has held it in 18 quarters since.
  • Royal Bank of Canada's Avalo Therapeutics position peaked at $872K in Q4 2024.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.